| Health Care Technology Industry | Healthcare Sector | Aamir Mahmood CEO | XFRA Exchange | SE0009268717 ISIN |
| SE Country | 8 Employees | - Last Dividend | - Last Split | - IPO Date |
Acarix AB (publ) is a pioneering medical device company founded in 2009, with its headquarters situated in Malmö, Sweden. It focuses on the development of innovative solutions designed for the rapid rule-out of coronary artery disease (CAD) using advanced AI technologies. The company has established itself in the global market by offering its state-of-the-art diagnostic aids in countries across the Nordic region, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. Acarix AB leverages sensitive acoustics and sophisticated computational processing to enhance the accuracy and efficiency of CAD diagnosis, aiming to improve patient outcomes and streamline healthcare processes.
This innovative point-of-care diagnostic aid is at the forefront of Acarix AB's product lineup. The CADScor System utilizes the company's groundbreaking technology to analyze the acoustics of coronary blood flow, combined with advanced computational processing. Its primary use is in the rapid rule-out of coronary artery disease (CAD), offering clinicians a non-invasive, highly sensitive tool for assessing patients. By employing this system, healthcare practitioners can quickly identify patients who may need further cardiovascular diagnostic assessments, thereby optimizing the care pathway and reducing unnecessary hospital referrals and diagnostics.